InMed Pharmaceuticals Inc
INM - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.79M
Close$
$5.56
241.3% upside
Current Fair Value
241.3% upsideUndervalued by 241.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $8.79 Million |
|---|---|
| Enterprise Value | $-2,185,623,024.00 |
| Earnings per Share | $-3.12 |
| Beta | 0.93 |
| Outstanding Shares | 4,373,290 |
Return
| Return on Equity | -126.94% |
|---|---|
| Return on Assets | -45.04% |
| Return on Invested Capital | -131.51% |
Valuation & Multiples
| P/E Ratio | -0.46 |
|---|---|
| PEG | -0.01 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | -0.47 |
| Enterprise Value to EBIT | 1.55 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 23, 2026
EPS Estimate
$-94.44
Consensus analyst estimateRevenue Estimate
$2.06 B
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-94.44
Consensus analyst estimateRevenue Estimate
$300,000
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About InMed Pharmaceuticals Inc
20 employees
CEO: Eric Adams
InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol ('CBN'), in diseases with high unmet medical need. T...